A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910